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Aim:To test for anti-endothelial and anti-neurotrophic effects from autoantibodies in sub-
sets of diabetes having open-angle glaucoma, dementia, or control subjects.
Methods: Protein-A eluates from plasma of 20 diabetic subjects having glaucoma or sus-
pects and 34 age-matched controls were tested for effects on neurite outgrowth in rat
pheochromocytoma PC12 cells or endothelial cell survival. The mechanism of the diabetic
glaucoma autoantibodies’ neurite-inhibitory effect was investigated in co-incubations with
the selective Rho kinase inhibitor Y27632 or the sulfated proteoglycan synthesis inhibitor
sodium chlorate. Stored protein-A eluates from certain diabetic glaucoma or dementia
subjects which contained long-lasting, highly stable cell inhibitory substances were char-
acterized using mass spectrometry and amino acid sequencing.
Results: Diabetic primary open angle glaucoma (POAG) or suspects (n=20) or diabetic
dementia (n=3) autoantibodies caused significantly greater mean inhibition of neurite out-
growth in PC12 cells (p<0.0001) compared to autoantibodies in control diabetic (n=24)
or non-diabetic (n=10) subjects without glaucoma (p<0.01). Neurite inhibition by the
diabetic glaucoma autoantibodies was completely abolished by 10µM concentrations of
Y27632 (n=4). It was substantially reduced by 30 mM concentrations of sodium chlorate
(n=4). Peak, long-lasting activity survived storage ×5 years at 0–4˚C and was associated
with a restricted subtype of Ig kappa light chain. Diabetic glaucoma or dementia autoan-
tibodies (n=5) caused contraction and process retraction in quiescent cerebral cortical
astrocytes effects which were blocked by 5µM concentrations of Y27632.
Conclusion: These data suggest that autoantibodies in subsets of adult diabetes having
POAG (glaucoma suspects) and/or dementia inhibit neurite outgrowth and promote a reac-
tive astrocyte morphology by a mechanism which may involve activation of the RhoA/p160
ROCK signaling pathway.
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INTRODUCTION
Glaucoma is a chronic neurodegenerative disorder affecting retinal
ganglion cells (RGC) and is a leading cause of blindness worldwide
(Quigley, 2011). Glaucoma has been reported to increase in older
adults with type 2 diabetes mellitus (Klein et al., 1994; Goldacre
et al., 2012), and in certain populations having Alzheimer’s demen-
tia (Tamura et al., 2006), although the mechanisms for these
associations are unclear. The aim of the present study was to test
the hypothesis that autoantibodies having anti-endothelial and
anti-neuronal effects increase in older adults with type 2 diabetes
and primary open angle glaucoma (POAG). We examined 20 older
adults with type 2 diabetes and glaucoma, 34 age-matched adults
without glaucoma (24 diabetic and 10 non-diabetic subjects), and
5 adults having diabetes and dementia for plasma autoantibodies
which could inhibit neurite outgrowth in PC12 cells or decrease
endothelial cell (EC) survival.
Humoral autoimmunity has been implicated in the etiology
of certain forms of glaucoma (Tezel and Wax, 2004) including
evidence for increased circulating autoantibodies to optic nerve
head heparan sulfate proteoglycans (HSPG) in subsets of nor-
mal tension or POAG (Tezel et al., 1999). Anti-neuronal HSPG
autoantibodies (having anti-neuronal and anti-endothelial effects)
were reported in adult type 2 diabetes in association with cer-
tain microvascular complications including painful neuropathy
(Zimering et al., 2011). The diabetic neuropathy plasma IgG
autoantibodies induced EC contraction, EC apoptosis, and inhib-
ited neurite outgrowth through a mechanism involving activa-
tion of the Rho A/Rho kinase signaling pathway (Zimering and
Pan, 2009; Zimering et al., 2011). The Rho A/Rho kinase sig-
naling pathway is present in diverse cell types (neurons, astro-
cytes, and endothelial-like trabecular meshwork cells) implicated
in the pathophysiology of glaucoma (Tura et al., 2009; Kumar
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and Epstein, 2011; Kameda et al., 2012). Our hypothesis is that
autoantibodies capable of binding to HSPG expressed on neurons,
astrocytes, and ECs and activating Rho A/Rho kinase signaling may
be capable of mediating axonal injury, ischemia, and glial reactivity
underlying early glaucomatous changes (Crish and Calkins, 2011)
leading to vision loss.
We now report that plasma IgG autoantibodies from dia-
betic POAG or suspects (n= 20) significantly inhibited neurite
outgrowth in PC12 cells (p< 0.0001) compared to autoanti-
bodies from diabetic (n= 24) or non-diabetic (n= 10) subjects
without glaucoma. The neurite outgrowth inhibitory activity in
four of four diabetic (POA) glaucomatous plasma autoantibod-
ies tested was completely abolished by co-incubating PC12 cells
with 10µM concentrations of Y27632, a selective Rho kinase
inhibitor. The neurite-inhibitory activity was also significantly
reduced in the presence of 30 mM sodium chlorate which sub-
stantially reduces HSPG expression in PC12 cells. Taken together,
these data suggest possible involvement of cell surface HSPG and
activation of the Rho A/Rho kinase signaling pathway in the mech-
anism for PC12 neurite inhibition by diabetic glaucoma plasma
autoantibodies.
MATERIALS AND METHODS
SUBJECTS
Informed consent for the Investigational Review Board (IRB)
approved substudy to the Veterans Affairs Diabetes Trial (VADT)
was obtained from all subjects. Fifteen of 89 subjects enrolled at
the VA New Jersey Healthcare System (VANJHCS) study site to
the VADT had a diagnosis of POAG or glaucoma suspect. Eleven
of the 15 VADT subjects were included in the study based on
the availability of an aliquot of plasma stored at −70˚C necessary
for protein-A affinity chromatography to obtain IgG autoantibod-
ies. The four excluded subjects included two non-Hispanic white
glaucoma subjects, one African-American glaucoma suspect and
one non-Hispanic white glaucoma suspect. A control group of 21
VADT subjects without glaucoma or suspicion of glaucoma was
randomly selected from among the remaining patients in whom
baseline plasma was available for analysis. Twenty-two additional
diabetic or non-diabetic glaucoma subjects or controls all evalu-
ated in an IRB-approved VANJHCS study were selected for further
analysis of the association between diabetic POAG and plasma
autoantibodies.
DIAGNOSTIC METHODS AND SUBGROUPS
Glaucoma or suspects
All subjects were evaluated by the optometry and/or ophthalmol-
ogy staff at the Veterans Affairs New Jersey Healthcare System.
The diagnosis of POAG was based on findings from a combi-
nation of test modalities including: dilated fundoscopic exam-
ination, applanation tonometry, gonioscopy, pachymetry, peri-
odic Humphrey visual field testing, or the results of Humphrey
visual field tests, dilated fundoscopic examination, and tonometry
performed by outside ophthalmologists and reported to optome-
try/ophthalmology specialists at the VANJHCS. Glaucoma suspect
is defined as a high risk individual with asymmetric cup to disk
(C/D) enlargement, equivocal neural rim narrowing, or retinal
nerve fiber layer thinning, but without definite evidence for visual
field loss. Subjects with increased intraocular pressure (IOP) alone,
but without C/D enlargement were not included in the primary
analysis, e.g., ocular hypertension (n= 1). Because many patients
were already being treated with IOP-lowering medications at the
time of study enrollment, it was not possible to distinguish sub-
groups of normal tension glaucoma vs. high-pressure POAG.
Patients with secondary forms of glaucoma such as neovascular
glaucoma (n= 1), or corticosteroid-associated glaucoma (n= 1)
were excluded from the analysis. Subjects with other ocular or
neuropathologies previously associated with potent EC autoanti-
bodies, but lacking diabetic painful neuropathy, e.g., central reti-
nal artery occlusion (n= 1), dementia (n= 1), or stroke (n= 1)
were excluded from the analysis. Painful diabetic neuropathy was
defined as the presence of characteristic findings on clinical exam-
inations performed by expert neurologists as previously reported
(Zimering et al., 2011). Diabetic nephropathy was defined as uri-
nary albumin excretion ≥300 mg/g creatinine or urinary protein
excretion ≥500 mg/g creatinine.
Diabetes and dementia (n= 3+ 2)
In three VADT patients who developed dementia at the end of
the clinical trial, neurite-inhibitory activity in PC12 cells was ana-
lyzed (Figure 1) as a control for the results in glaucoma, another
type of chronic neurodegenerative disorder. Patient #1 was a 68-
year-old African-American male with POAG, long-standing type
2 diabetes without significant diabetic retinopathy who was diag-
nosed with glaucoma at the onset of his VADT participation. His
mild visual field loss was stable over a 7-year observation period;
he was diagnosed with Alzheimer’s type dementia. Patient #2 is a
71 year old non-Hispanic white male with type 2 diabetes, ocu-
lar hypertension without baseline visual field loss whose visual
fields were stable and cup/disk ratio was normal over a 5-year
observation period; he was diagnosed with dementia secondary
to traumatic brain injury. Patient #3 was a 75-year-old non-
Hispanic white male with long-standing type 2 diabetes, no evi-
dence of glaucoma, and mixed fronto-temporal and multi-infarct
dementia.
Two additional subjects having diabetes and dementia were
included in the analysis of EC inhibitory activity in stored protein-
A eluates (Table 3). Patient #4 is a 70-year-old VADT subject
who had type 2 DM, mild diabetic retinopathy, and later devel-
oped Alzheimer’s type dementia. Patient #5 is a 53-year-old type 1
DM (non-VADT) patient who had a wide spectrum of microvas-
cular complications including nephropathy leading to end stage
renal disease, multiple recurrent small vessel strokes (Zimering,
2010) progressing to dementia, proliferative diabetic retinopathy,
autonomic and painful neuropathy, and glaucoma possibly due to
steroid use.
Blood drawing
Baseline plasma samples were obtained from study subjects
prior to initiation of treatment in the VADT substudy. Plasma
bFGF was determined with a sensitive specific two-site IRMA
as previously described (Zimering et al., 2009a). Bioactivity in
protein-A eluate fractions was previously shown to be stable
for 5 years or longer at −20˚C (Zimering and Thakker-Varia,
2002).
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FIGURE 1 | Diabetic glaucomatous autoantibodies inhibit neurite
expression in PC 12 cells (A) highest neurite-inhibitory activity was
associated with glaucomatous vision loss (B) and was eliminated by
treatment withY27632 (C) or 30mM sodium chlorate (D). (A-D)Thirty
microgram per milliliter concentrations of the protein-A eluate fraction of
plasma was incubated with PC12 cells in the presence or absence of 10µM
concentrations of Y27632 (C) or 30 mM concentrations of sodium chlorate (D)
as described in Section “Materials and Methods.” Results (mean±1 SD of
four different protein-A eluates) are expressed as % neurite expression
compared to cells incubated with 10 ng/mL concentrations of basic fibroblast
growth factor alone [i.e., 100%, open bars (C,D)]. DM, diabetes mellitus; Glc,
glaucoma or suspect (susp); Dmt, dementia; VF, visual field.
Neurite outgrowth inhibition assay
Undifferentiated rat pheochromocytoma PC12 cells obtained
from ATCC (Manassa,VA, USA) were grown in DMEM containing
10% horse serum, 5% fetal calf serum, and 10 ng/mL bFGF was
added in order to induce neuronal differentiation. Test protein-
A eluate fractions (1:50 dilution= 30µg/mL protein) were added
to cells in duplicate or triplicate and incubated at 37˚C for 48 h.
Next the proportion of cells expressing a neurite of ≥2 cell diam-
eters in length was counted and compared to the proportion of
bFGF-stimulated neurite cell expression in dishes containing bFGF
without added test fractions as previously described (Zimering
et al., 2011). Rho kinase-dependence of the neurite inhibition
was assessed by co-incubating cells in the presence or absence
of 10µM concentrations of Y27632, a selective inhibitor for the
Rho-associated protein kinase, p160ROCK (Uehata et al., 1997).
Dependence of neurite-inhibitory effects in the diabetic protein-
A eluates on cell surface sulfated proteoglycans was tested by
comparing results in to pheochromocytoma PC12 cells grown
in the presence or absence of 30 mM sodium chlorate, a treat-
ment which substantially reduces HSPG expression in the cells
(Hoogewerf et al., 1991).
Endothelial cell survival assay
Bovine pulmonary artery ECs (Clonetics, Inc., San Diego, CA,
USA) were grown in Medium 199 plus 10% fetal calf serum and
EC growth medium (EGM, Clonetics, Inc., San Diego, CA, USA).
EC survival in the presence or absence of diabetic plasma protein-A
eluates (30µg/mL) was assessed after 48 h incubation as previously
described (Zimering et al., 2011). Results represent the mean (±1
SD) of quadruplicate determinations.
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Human lymphoblast cell culture
Human lymphoblasts (GM 01500) from a patient having light
chain amyloidosis (AL disease) were obtained from the Human
Mutant Repository, Coriell Institute (Camden, NJ, USA), and
grown in RPMI 1640 containing 2 mM l-glutamine, 10% fetal calf
serum. The cell supernatant was subjected to sequential protein-
A affinity chromatography followed by antihuman IgG affinity
chromatography in order to obtain partially purified monoclonal
human IgG for testing of EC bioactivity.
Protein-A affinity chromatography
The IgG fraction of plasma was isolated using protein-A affinity
chromatography as previously reported (Zimering et al., 2011).
Antihuman IgG affinity chromatography
The protein-A eluate fraction obtained after applying 1.0 mL of the
human lymphoblast (GM 01500) cell supernatant to a protein-A
affinity column (1.0 mL) was adjusted to pH 7.0 by adding 1 M
Tris pH 9.0. The eluate was then diluted 1:1 with an equal vol-
ume of 100 mmol/L Tris pH 8.0 and applied to a goat antihuman
IgG agarose column (1.0 mL), washed with 5 mL of 100 mmol/L
Tris pH 8.0, and eluted stepwise with 5× 1.0 mL aliquots of
100 mmol/L sodium citrate, pH 3.0. The second eluate fraction
contained nearly all of the recovered protein and it was adjusted to
pH 7.0 with 1 M Tris pH 9.0 prior to sterile filtration and testing
of biological activity.
Cerebral cortical astrocytes
Rat cerebral cortices were dissociated and placed in polylysine-
coated T-75 flasks containing minimal essential medium without
phenol red and 15% fetal bovine serum (having low estradiol
concentration)-NM-15. They were fed on day 3 with fresh NM-15
medium. On day 10, the flasks were shaken overnight at 250 rpm.
The next day, the medium was removed, the cells were rinsed with
warm PBS, and then fresh NM-15 containing 10 mM AraC was
added to the cells. Two days later, the cells were trypsinized and
plated at 250,000 cells per dish in polylysine-coated 35 mm dishes
containing NM-15. After 2–3 weeks in serum-containing medium,
a small percentage of the astrocytes (1–5%) spontaneously differ-
entiated from a flat polygonal shape into cells having a “stellate”
appearance, bearing one or more thick processes located proximal
to the cell body or several thin long branching processes located
distal to the cell body. The acute effects of diabetic plasma autoan-
tibodies on astrocyte morphology were assessed in cells that had
been maintained for 2–3 weeks in culture. Cell viability was good
under these long-term culture conditions.
Time-lapse photomicroscopy
Stellate-appearing astrocytes (and surrounding less differentiated
cells) were imaged under high power magnification using a Nikon
TMS microscope at 200×magnification. Following bath applica-
tion of a 1:100 dilution (3–20µg/mL) of protein-A eluates from
diabetic glaucoma or control subjects, cells were observed contin-
uously for acute change in morphology. Baseline and follow-up
images were captured using a Nikon camera connected to the
microscope with a phototube every 5 min for a period up to
30–45 min after addition of protein-A eluates.
Heparin Sepharose affinity chromatography
Heparin Sepharose (HS) affinity chromatography was carried out
as previously reported (Zimering et al., 2009a).
SELDI mass spectrometry
Mass spectrometry was carried out as previously reported (Zimer-
ing et al., 2011).
Protein sequencing
Amino acid sequencing was carried out on the Applied Biosys-
tems (Foster City, CA, USA) Procise®494 protein sequencer using
standard Edman sequencing. The resulting chromatographs were
analyzed using Model 610A software.
Furin digests of diabetic protein-A eluates
Two microliters of an aqueous solution containing human recom-
binant furin (≥2000 units/mL) was added to 40µL of protein-A
eluates (8µg protein) from each of three diabetic subjects in buffer
containing 100 mmol/L Tris, pH 7.0, and 200µM calcium. Fol-
lowing 180 min incubation at 25˚C, 4µL aliquots of furin-treated
or -untreated protein-A eluates were added in quadruplicate to
ECs for testing of biological activity. The remaining aliquot of
furin-treated and -untreated paired samples was subjected to mass
spectrometry which revealed a decrease in the peak 23 kDa appar-
ent light chain MW species (present in untreated samples) in
paired samples subjected to furin digestion.
Chemicals
Protein-A agarose was obtained from Pierce Chemical Co. (Rock-
ford, IL, USA). Goat antihuman IgG (whole molecule) agarose was
obtained from Sigma Chemical Co. (St. Louis, MO, USA). Human
recombinant furin was obtained from Sigma Chemical Co. (St.
Louis, MO, USA). All other chemicals and reagents were analytical
grade.
Protein determinations
Protein concentrations were determined by a bicinchoninic acid
protein assay kit (Pierce Chemical Co., Rockford, IL, USA).
Statistics
All data are the mean± 1 SD as indicated. Comparisons were made
by paired and unpaired Student’s t -tests, or Fischer’s exact test as
indicated.
RESULTS
ASSOCIATION BETWEEN DIABETIC GLAUCOMA OR GLAUCOMA
SUSPECT AND RACE
Diabetic subjects with POAG or POAG suspects included a sig-
nificantly higher proportion of African-American or subjects of
Afro-Caribbean descent compared to diabetes without glaucoma
(Table 1). Mean baseline diastolic blood pressure was significantly
higher in diabetes having POAG or suspects than in diabetes with-
out glaucoma (Table 1). It was also higher in a control group of
non-diabetic subjects without glaucoma (Table 1). There was a
trend of a significant association (p= 0.06) between low plasma
basic fibroblast growth factor (0–3.4 pg/mL) and an increased pro-
portion of diabetic subjects having POAG or suspects vs. no POAG
or suspect (100 vs. 69%; Table 1).
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Table 1 | Baseline clinical characteristics in the study subjects.
Risk factor Diabetes No diabetes
No Glc
(N =24)
Glc or susp
(N =20)
P -value* No Glc
(N =10)
Age (years) 65.2±8.3 69.6±12.3 0.16 68.0±16.7
Race (NHW/AA/H) (22/1/1) (9/10/1) 0.0006∧ (5/4/1)
BMI (kg/m2) 32.0±5.1 32.0±6.9 0.99 31.2±7.7
DM duration (years) 11.0±6.9 13.9±10.0 0.28 NT
Hba1c (%) 8.3±1.4 8.3±1.5 0.95 NT
Syst bp (mm Hg) 129.9±10.9 133±13.6 0.48 124±7.4
Diast bp (mm Hg) 67.6±8.9 74.6±9.1 0.01 76±7.0a
Total Chol (mg/dL) 172±14 176±41 0.78 174±51
Low bFGF (%) 69 (16) 100 (11) 0.06∧ NT
Insulin use (%) 39 60 0.18∧ NT
Results are mean±1 SD or proportion; (), number tested; Glc, glaucoma; susp,
suspect; bp, blood pressure; Chol, cholesterol; Low bFGF, basic fibroblast growth
factor=<4 pg/mL; ∧Fischer’s exact test; *P-value for comparison of diabetics
with or without glaucoma. NHW, non-Hispanic white, AA, African-American, H,
Hispanic, aP=0.016 compared to diabetes without glaucoma.
ASSOCIATION BETWEEN DIABETIC GLAUCOMA (SUSPECT) AND
PAINFUL NEUROPATHY OR FAMILY HISTORY OF DEMENTIA
Low plasma basic fibroblast growth factor was associated with
a significantly increased occurrence of EC inhibitory autoanti-
bodies in older adult type 2 diabetes from the VADT (Zimering
et al., 2009a). Since baseline EC inhibitory autoantibodies pre-
dicted an increased risk for certain microvascular complications
in the VADT substudy (Zimering et al., 2009b), we tested for
associations between diabetic POAG and EC inhibitory autoanti-
bodies or co-morbid diabetic microvascular complications. A sig-
nificantly higher proportion of diabetic subjects with POAG or
suspects (65 vs. 25%) had inhibitory EC autoantibodies com-
pared to the proportion of diabetic subjects without glaucoma
(p= 0.014; Table 2). Painful neuropathy was significantly more
prevalent among diabetic POAG or suspects compared to diabetes
without POAG (p= 0.014; Table 2). First-degree relatives (mother,
father) of diabetic POAG or suspects were significantly more likely
to have had Alzheimer’s dementia as a contributory cause of death
compared to the parents of diabetic subjects without glaucoma
(3/11 vs. 0/20; p= 0.04, Table 2).
NEURITE OUTGROWTH INHIBITORY ACTIVITY IN DIABETIC PROTEIN-A
ELUATES: ASSOCIATION WITH GLAUCOMATOUS VISION LOSS OR
DEMENTIA
Mean PC12 neurite outgrowth inhibitory activity in the protein-A
eluates (1:50 dilution;∼30µg/mL) of plasma from diabetic POAG
or suspects significantly exceeded mean inhibitory activity from
diabetes without glaucoma (55.7± 24 vs. 99.0± 12%; p< 0.0001;
Figure 1A). It was also significantly more inhibitory (p= 0.002)
compared to mean activity in protein-A eluates from subjects with-
out diabetes and without glaucoma (94.2± 5%; Figure 1A). The
protein-A eluates of three diabetic subjects who later developed
dementia had the most potent mean neurite-inhibitory activity
(44± 3%). It significantly exceeded mean inhibitory activity in
Table 2 | Association between diabetic glaucoma or suspect and
co-morbid microvascular complications or family history of dementia.
Risk factor Diabetes
No Glc
(N =24)
Glc or susp
(N =20)
P -value*
ME, AMD (%) 12.5 30 0.26
Nephropathy (%) 25 15 0.48
Painful neuropathy (%) 25 65 0.014
Inhibitory EC Actc (%) 25 65 0.014
FH of dementia (%) 0 (20) 27 (11) 0.04
Results are proportion; (), number tested; Glc, glaucoma, susp, suspect, *Fis-
cher’s exact test, comparison of diabetics with or without glaucoma; ME, macular
edema, AMD, age-related macular degeneration, FH, family history in a 1˚ rela-
tive of Alzheimer’s dementia; csignificant inhibitory endothelial cell (EC) activity,
defined as ≤90% of basal cell number as described in Section “Materials and
Methods.”
IgG from diabetes without glaucoma (p< 0.0001, Figure 1A).
Diabetic glaucomatous vision loss (n= 11 subjects) was asso-
ciated with significantly more inhibitory mean PC 12 neurite
activity compared to mean activity in the protein-A eluates from
nine diabetic POAG suspects (45.5± 14 vs. 74.6± 31; p< 0.05;
Figure 1B).
EFFECT OF RHO KINASE INHIBITOR ON NEURITE-INHIBITORY ACTIVITY
IN DIABETIC PLASMA PROTEIN-A ELUATES
The Rho A/Rho kinase signaling pathway plays an important
role in axonal pathfinding during development (Dickson, 2001).
Y27632 is a selective inhibitor of Rho kinase (Ishizaki et al., 2000).
Diabetic glaucomatous plasma autoantibodies (30µg/mL) from
four African-American patients having moderate or severe pro-
gressive glaucomatous visual loss caused significant inhibition of
neurite outgrowth in PC 12 cells (Figure 1C). The mean inhibitory
activity from the four protein-A eluates was significantly reduced
(p< 0.001) by co-incubating PC12 cells with 10µM concentra-
tions of Y27632 (Figure 1C). Similar concentrations of Y27632
alone had no significant effect on PC12 cell neurite expression
compared to cells exposed to bFGF (10 ng/mL) without Y27632
(Figure 1C).
EFFECT OF REDUCED SULFATED PROTEOGLYCAN EXPRESSION IN
PC 12 CELLS
Sodium chlorate substantially reduces the sulfation of proteogly-
cans in various cells (Hoogewerf et al., 1991). To test for possible
involvement of sulfated proteoglycan (e.g., HSPG) in the mech-
anism for neurite inhibition in diabetic glaucomatous plasma
protein-A eluates, PC12 cell cultured in the presence or absence of
30 mM sodium chlorate were incubated with the protein-A eluate
fractions (30µg/mL) of plasma from four diabetic subjects with
POAG. The mean neurite-inhibitory activity in all four protein-
A eluates (Pt 1–4 AB) (assayed individually) was significantly
reduced (P < 0.0001) in the PC12 cells cultured in the presence
of 30 mM sodium chlorate compared to PC12 cells grown in stan-
dard medium (DMEM with 1% FCS) in the absence of chlorate
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ion (solid bars, Figure 1D). PC12 cell viability was unaffected by
the presence of 30 mM chlorate. Neurite expression did not dif-
fer significantly in cells grown in the presence of bFGF with or
without 30 mM chlorate (open bars, Figure 1D).
EFFECT OF DIABETIC PLASMA (POA) GLAUCOMATOUS
AUTOANTIBODIES ON ASTROCYTE MORPHOLOGY
Astrocytes play critical role(s) in maintenance of the blood-brain
barrier (Allen et al., 2010), protect neurons against glutamate-
induced excitotoxicity, and modulate blood flow to actively firing
neurons. To facilitate these important neuronal support roles,
astrocyte processes lie in close apposition to basement mem-
branes, capillaries, and neuronal synapses. Since the expression
of astrocytic processes, or stellation, is inhibited by activity in the
RhoA/Rho kinase signaling pathway (Abe and Misawa, 2003), we
next tested whether autoantibodies from diabetic POAG or control
subjects could inhibit astrocyte stellation in vitro. Plasma autoan-
tibodies (1:100 dilution= 3–20µg/mL) from five of five diabetic
glaucoma or suspects tested (n= 8 experiments) caused retrac-
tion of thick processes located proximal to the astrocyte cell body
(e.g., Figures 2A,B). Withdrawal of proximally located processes
was most rapid (occurring within 2–5 min) and more extensive
leading to disruption connectivity among processes in neighbor-
ing cells after bath application of low concentration (3µg/mL)
of diabetic POAG plus dementia autoantibodies (Figures 2C,D).
The retraction of thick astrocytic processes (induced by diabetic
glaucoma+ dementia autoantibodies) was prevented by pretreat-
ing cells (for 10 min) with 5µM concentrations of Y27632
FIGURE 2 | Effect of diabetic glaucomatous autoantibodies on astrocyte
morphology. Morphology in cerebral cortical astrocytes (A) before or (B)
30 min after addition of 10µg/mL concentration of protein-A eluate from type
2 DM and glaucoma; (C) before or (D) 10 min after addition of 3µg/mL
concentration of the protein-A eluate fraction from type 2 DM having
glaucoma and Alzheimer’s type dementia (Pt 1). Antibodies caused varying
degrees of withdrawal of thick astrocyte processes associated with increased
stress fiber expression (arrows), and cell contraction (vertical lines).
Astrocytes cultured in the presence of 10µM concentrations of Y27632 for
10 min before (E) and after (F) addition of a 3µg/mL concentration of the Pt 1
protein-A eluate fraction did not undergo similar changes in their appearance.
Results similar to those shown in (A–D) were obtained in eight experiments
using 3–10µg/mL concentrations of autoantibodies from five different
diabetic glaucoma patients. Much less if any acute change in morphology was
observed (n=4 experiments) using 10–20µg/mL concentrations of protein-A
eluate from four type 2 DM subjects without glaucoma.
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(Figures 2E,F; n= 2 experiments). Y27632 alone had no effect on
astrocyte morphology (not shown in Figure 2). Control plasma
autoantibodies (10–20µg/mL) from four of four age-matched,
non-diabetic subjects without glaucoma (or suspicion of glau-
coma) tested had little or no significant effect on the morphology
of astrocyte thick processes (n= 4 experiments, not shown in
Figure 2). The active autoantibodies (10–20µg/mL) from two
of the diabetic glaucoma subjects that caused retraction of thick
astrocyte processes had no apparent significant effect on mor-
phology of thinner more distally located processes found in sev-
eral highly differentiated, extensively branching astrocytes (n= 2
experiments, each observed for 30 min).
FURIN TREATMENT UNMASKED POTENT ENDOTHELIAL CELL
INHIBITORY ACTIVITY IN DIABETIC DEMENTIA PROTEIN-A ELUATE
Mean EC inhibitory activity in the protein-A eluates from subsets
of diabetic macular edema or nephropathy (n= 6) or in diabetic
dementia plasma (n= 5) significantly exceeded mean activity in
protein-A eluates from diabetic non-glaucoma or glaucoma sus-
pects (Table 3). After 9 months storage of Patient 4 and 5 diabetic
dementia protein-A eluates, a significantly more inhibitory form
of EC activity appeared spontaneously (Table 3) having similar
magnitude to the inhibitory activity recovered from the Patient
1 diabetic dementia and glaucoma protein-A eluate following
brief exposure to the proprotein convertase (PC) furin (Table 3).
Mass spectrometry or amino acid sequencing of long-term stored
protein-A eluates from four of four diabetic dementia plasmas
tested revealed either peak 23 kDa MW species or 86–89% amino
acid sequence homology to human kappa (κ) light chain variable
regions. In an adult type one DM patient (Patient 5) who suffered a
severe unremitting course of microvascular and neuropathic com-
plications (Zimering, 2010) including multi-infarct dementia and
steroid-induced glaucoma, the protein-A eluate retained its potent
neurite-inhibitory activity after 5 years storage at 0–4˚C. Half-
maximal inhibition in EC survival occurred at concentrations of
Table 3 | Effect of long-term storage of protein-A eluates or furin
digestion on EC activity.
Diabetic subset Endothelial cell bioactivity (%)
Before After P -value*
LONG-TERM STORAGE (9–60MONTHS)
No glaucoma or susp (n=4) 107.3±6.1 108±6.3 0.87
Glaucoma suspect (n=4) 98.7±5.3 86.8±20.2 0.20
Macular edema/nephr. (n=6) 81.2±5.8† 86.5±14.8 0.47
Dementia (n=5) 81.2±3.3† 66.5±4.5 (2) 0.01
FURIN
Pt 1: glaucoma+Alz dementia
(n=1)
80±8 65±3 0.02
Pt 2: OHT+dementia (n=1) 82±11 87±4 0.63
Results are mean,±1 SD, endothelial cell bioactivity was determined as described
in Section “Materials and Methods.” *P-value from Student’s t-test comparing
results before and after storage or furin treatment † P<0.0001 compared to mean
activity (before storage) in group of glaucoma suspects. OHT, ocular hypertension.
Patient 5 IgG (30 nM) which were comparable to the half-maximal
inhibitory concentrations (10 nM) observed in the purified mon-
oclonal IgG2 kappa light chains obtained from a clone of human
lymphoblasts (GM01500) from a patient having multiple myeloma
and systemic light chain AL (data not shown). Using HS affinity
chromatography, we were able to obtain a highly purified peak EC
inhibitory fraction in the Patient 5 protein-A eluate which eluted
from HS column with 0.1 M NaCL. Comparison of the amino acid
sequences in the Patient 5 peak, HS-purified fraction to its starting
material protein-A eluate or to AL disease monoclonal IgG2 kappa
light chains revealed the presence of proline at amino acid position
12 in the peak HS-purified Patient 5 diabetic eluate only. Proline
at amino acid position 12 is characteristic of a restricted subgroup
of kappa II gene-encoded sequences (Wu and Kabat, 1970).
DISCUSSION
The present data are the first to suggest that plasma autoantibod-
ies from a subset of older adult type 2 diabetes having POAG or
suspects cause significant inhibition of neurite outgrowth in PC
12 cells via a mechanism which may involve binding to cell surface
HSPG and activation of intracellular Rho kinase. Our results are
consistent in part with earlier reports of increased titers of autoan-
tibodies specific for (optic nerve head) HSPG in subsets of normal
tension or primary angle glaucoma having a systemic autoimmune
disease (Tezel et al., 1999).
Unlike systemic lupus erythematosus (SLE), type 2 diabetes is
not a systemic autoimmune condition. Yet autoantibodies capa-
ble of inducing EC apoptosis were described in subsets of SLE
nephropathy (van Paassen et al., 2007) or in older adult type 2
diabetes in association with macular edema, nephropathy, and/or
painful neuropathy (Zimering and Pan, 2009). The present find-
ing of a significant association between the occurrence of diabetic
painful neuropathy and POAG is novel. Taken together with the
chlorate sensitivity of the PC12 neurite-inhibitory activity in dia-
betic glaucoma autoantibodies it suggests HSPG (or a closely
related sulfated proteoglycan) as a possible common target for
autoantibodies in diabetic POAG and diabetic painful neuropathy.
Heparan sulfate glycosaminoglycans (GAGs) play important
roles in early brain development (Inatani et al., 2003) including
ensuring retinal axon guidance to the optic nerve head (Ogata-
Iwao et al., 2011) and the correct topographic arrangement of
axons in the optic nerve (Lee et al., 2004). HSPG are ubiquitously
expressed on the cell surface of ECs, mesenchyme-derived cells
and neurons. Following CNS injury, astrocyte HSPG increases its
sulfation (Properzi et al., 2008). Basic fibroblast growth factor is
a known neurotrophic and survival factor in RGC (Soto et al.,
2006) which requires HSPG for its biological activity. Anti-HSPG
autoantibodies may interfere with the survival-promoting effects
of locally available bFGF in RGCs or contribute to generally low
plasma bFGF in diabetic glaucoma. Autoantibody-induced neu-
rite retraction may deprive optic axons of trophic support from
postsynaptic target neurons. Reversal of astrocyte stellation in
association with stress fiber expression and astrocyte contraction
suggests that the diabetic glaucoma autoantibodies which induced
morphological astrocyte reactivity (Tura et al., 2009) may lead to
loss of glial-neuron interaction(s) which is an important source of
trophic support in RGCs.
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Ten of eleven diabetic subjects who suffered POAG-related
visual field loss were African-American or of Afro-Caribbean ori-
gin, groups especially prone to develop POAG or glaucomatous
blindness (Marshall, 1989). Our findings of generally low plasma
bFGF among diabetic glaucoma or suspects is consistent with an
earlier report of a significant association between low plasma bFGF
and African-American race in a multi-ethnic VADT substudy of
older adults having type 2 diabetes (Zimering et al., 2008). Higher
mean diastolic blood pressure in the current diabetic glaucoma
group may reflect (in part) inclusion of a higher proportion of
African subjects. It is also consistent with a reported association
between increased diastolic blood pressure and raised IOP in older
adults having diabetes (Klein et al., 1994).
The prevalence of glaucoma among blacks living in certain geo-
graphically isolated areas is striking. It suggests possible involve-
ment of population- or race-specific hereditary predisposition
factor(s). For example, in the Barbados Eye study, the prevalence
of POAG among older adult Afro-Caribbean men and women
(age 70 years or above) was 17%; it was eight times higher than
in Barbadian whites, and could not be accounted for by diabetes
or hypertension (Leske et al., 1994). One possible contributory
factor is known hereditable differences in autoantibody subclass
concentrations. African-American children had higher concen-
trations of plasma total IgG and the IgG2 subclass compared to
Caucasian children (Shackelford et al., 1985). Km1 is a marker
in the constant region of kappa light chains which occurs with
3.7-fold higher frequency in African-American compared to Cau-
casian populations (Granoff et al., 1984). Km1 was associated with
increased IgG2 antibody response to certain polysaccharide anti-
gens in African-American children (Granoff et al., 1984); and the
IgG2 antibody response (associated with Km1) was predominated
by expression of a particular subgroup of less prevalent kappa light
chain (κ IIa) genes (Lucas et al., 1991). A kappa II gene is predicted
to have encoded the peak inhibitory kappa light chain in the eluate
from (type 1 DM) Patient 5 having severe disease manifestations
(Zimering, 2010). In contrast, in Caucasian adults, an increased
IgG2 antibody response to several different common polysaccha-
ride bacterial antigens was associated with Gm23, a marker in
the heavy chain constant region (Ambrosino et al., 1985). Gm23
was reported to be associated with a significantly increased risk of
diabetic retinopathy (Stewart et al., 1993). Our finding of a signif-
icantly increased risk for Alzheimer’s dementia among the parents
of diabetic glaucoma or suspects is consistent with the possibility
that a subset of autoantibodies having highly potent (neurite-, EC
and glial-) inhibitory properties may reflect inheritance of a par-
ticular subgroup of kappa light chain genes. Increased prevalence
of such genes as the kappa II (Ig) gene subgroup in persons of
African descent may reflect an earlier evolutionary selection pres-
sure that acted to increase the prevalence of a survival-promoting,
beneficial allele. The later occurrence of slow neurodegenerative
diseases such as open angle glaucoma or Alzheimer’s dementia in
persons harboring potent kappa light chain autoantibodies is con-
sistent with the concept of “antagonistic pleiotropy,” advanced by
Williams (1957). Williams postulated that senescence-associated
mortality occurs through the selection of genes which confer an
early reproductive (survival) benefit yet harbor additional latent
harmful effects to the organism which are expressed during aging.
Glaucoma is a slowly progressive neurodegenerative disease
whose severity is significantly affected by elevated IOP (Sommer,
1996; Quigley, 2011). IOP is thought to mediate remodeling of
the optic nerve head extracellular matrix (ECM) in part through
the activation of membrane-type matrix metalloproteinases (MT-
MMP) (Agapova et al., 2003). Furin is a proprotein convertase
(PC) which is expressed in vascular endothelial and trabecular
meshwork cells under conditions of increased hemodynamic or
mechanical stress (Negishi et al., 2001; Remacle et al., 2008). In
our prior work, long-term storage of certain cancer sera protein-A
eluates was associated with the spontaneous appearance of highly
potent EC inhibitory substances which were excitotoxic in rat
embryonic hippocampal neurons and had MW and amino acid
sequence characteristics of Ig kappa half-light chains (Zimering
et al., 2011). The current preliminary data are consistent with
the possibility that furin or a closely related PC which can rec-
ognize and cleave substrates at multi-basic amino acid sequences
(Remacle et al., 2008) causes gain-in-inhibitory function through
cleavage of certain IgGs at specific recognition sequences(s).
One possible recognition site (perhaps giving rise to kappa half-
light chains) is the K-(X)3-K-R sequence which is located in the
variable-constant switch region in certain κ light chains. The beta
site amyloid precursor protein cleaving enzyme 1 (Scholefield et al.,
2003), BACE1 (β-secretase), has been implicated in Alzheimer’s
disease pathogenesis because it generates amyloid β-peptide from
its precursor protein. Of interest, β-secretase (BACE1) is under
negative regulatory control through its binding to heparan sul-
fate (Scholefield et al., 2003). Certain members of the PC family
are expressed at the cell surface in association with HSPG (Mayer
et al., 2008). Thus localization of anti-HSPG autoantibodies at
such cell regions might provide a mechanism for dual activation
of β-secretase and for proteolytic processing of autoantibodies
leading to more highly potent, long-lasting inhibitory substances.
A limitation of our study is that it is small and the results princi-
pally reflect the experience of older African-American men having
POAG. More study in women and other racial groups is needed
to confirm the present findings and to determine whether PC12
neurite-inhibitory autoantibodies may increase in non-diabetic
glaucoma subjects. The mechanism(s) underlying glaucomatous
neurodegeneration are complex and multifactorial (Kuehn et al.,
2005). It is possible anti-HSPG autoantibodies may occur as a con-
sequence of tissue injury yet have only a limited, bystander role
in the neurodegenerative disease process. Although in vivo experi-
mental support of a pathogenic role for anti-HSPG autoantibodies
in glaucomatous neurodegeneration is lacking, in vitro effects of
the autoantibodies in ECs, neurons and cerebral cortical astro-
cytes support a potential role in promoting neurodegeneration
underlying glaucoma and dementia. Of interest, in a mouse model
of hereditary glaucoma, high-dose irradiation unexpectedly com-
pletely prevented the subsequent development of glaucomatous
RGC degeneration (Anderson et al., 2005). Basic FGF is released
following irradiation and it protects microvascular endothelium
against radiation-induced apoptosis (Fuks et al., 1994). More study
in a mouse model of irradiation-induced neuroprotection could
provide a test for involvement of bFGF or factors (anti-HSPG
autoantibodies) which negatively affect bFGF local bioavailabil-
ity in determining long-term RGC survival. Our data do not
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exclude the possible involvement of other kinds of autoreactive
antibodies, such as heat shock proteins (HSP) autoantibodies, or
cell-mediated immune mechanisms in retinal ganglion degener-
ation (Wax et al., 2008). For example, immunization with HSP
27 or HSP60 in the Lewis rat induced a glaucoma-like pattern
of RGC degeneration via activation of T cells which secreted Fas
ligand (Wax et al., 2008). Still evidence suggests that early acti-
vation of RGC survival pathways (perhaps mediated in part by
bFGF) may prevent or delay Fas ligand-induced RGC apoptosis
(Kim and Park, 2005).
The retinal inner limiting membrane (ILM) contains HSPG;
and the ILM undergoes thickening during aging (Candiello et al.,
2010) and in diabetes. In a subset of diabetic glaucoma or suspects
(3 of 20 subjects), protein-A eluates caused mild EC stimulation
suggesting that diabetic glaucomatous autoantibodies are het-
erogeneous and may include immune complexes. Trapping of
immune complexes in the retinal ILM might disrupt its barrier
function or lead to complement activation. A possible under-
lying role for humoral autoimmunity in subsets of dementia
is suggested by reports that autoantibodies cross-reactive with
vascular HSPG increased in serum from older adults having senile,
Alzheimer’s type dementia (Fillit et al., 1987). Brain tissue from
Alzheimer’s-type dementia patients showed diffuse deposition of
IgG, fibrinogen, and glial hyperreactivity indicative of loss of
EC barrier integrity (Ryu and McLarnon, 2009). More study is
needed to determine whether plasma diabetic autoantibody PC12
neurite-inhibitory activity may be a useful (early) marker for sus-
tained activation of Rho kinase in diverse cell types including
neurons, astrocytes, or ECs involved in mediating slowly, progres-
sive glaucomatous visual field loss, or in a subset of diabetes having
dementia.
ACKNOWLEDGMENTS
We thank Dr. Carlos Abraira, and Dr. William Duckworth, VADT
Co-Chairmen for their support. We thank Dr. Cheryl Dreyfus and
Dr. Janet Alder, Department of Neuroscience and Cell Biology,
UMDNJ-Robert Wood Johnson Medical School for generously
providing cerebral cortical astrocytes used in these experiments.
This study was supported by a grant (to Mark B. Zimering) from
the Veterans Biomedical Research Institute, East Orange, NJ, USA;
and by the Department of Veterans Affairs Cooperative Studies
Program, Office of Research and Development, Washington, DC.
REFERENCES
Abe, K., and Misawa, M. (2003). Astro-
cyte stellation induced by rho kinase
inhibitors in culture. Brain Res. Dev.
Brain Res. 143, 99–104.
Agapova,O. A.,Kaufman,P. L.,Lucarelli,
M. J., Gabelt, B. T., and Hernandez,
M. R. (2003). Differential expres-
sion of matrix metalloproteinases
in monkey eyes with experimental
glaucoma or optic nerve transection.
Brain Res. 967, 132–143.
Allen, C., Srivastava, K., and Bayraktu-
tan, U. (2010). Small GTPase RhoA
and its effector rho kinase mediate
oxygen glucose deprivation-evoked
in vitro cerebral barrier dysfunction.
Stroke 41, 2056–2063.
Ambrosino, D. M., Schiffman, G.,
Gotschlich, E. C., Schur, P. H.,
Rosenberg, G. A., DeLange, G. G.,
et al. (1985). Correlation between
G2m(n) immunoglobulin allotype
and human antibody response
and susceptibility to polysaccharide
encapsulated bacteria. J. Clin. Invest.
75, 1935–1942.
Anderson, M. G., Libby, R. T., Gould,
D. B., Smith, R. S., and John, S.
W. (2005). High-dose radiation with
bone marrow transfer prevents neu-
rodegeneration in an inherited glau-
coma. Proc. Natl. Acad. Sci. U.S.A.
102, 4566–4571.
Candiello, J., Cole, G. J., and Halfter,
W. (2010). Age-dependent changes
in the structure, composition and
biophysical properties of a human
basement membrane. Matrix Biol.
29, 402–410.
Crish, S. D., and Calkins, D. J. (2011).
Neurodegeneration in glaucoma:
progression and calcium-dependent
intracellular mechanisms. Neuro-
science 176, 1–11.
Dickson, B. J. (2001). Rho GTPases in
growth cone guidance. Curr. Opin.
Neurobiol. 11, 103–110.
Fillit, H. M., Kemeny, E., Luine, V., Wek-
sler, M. E., and Zabriskie, J. B. (1987).
Antivascular antibodies in the sera
of patients with senile dementia of
the Alzheimer’s type. J. Gerontol. 42,
180–184.
Fuks, Z., Persaud, R. S., Alfieri,
A., McLoughlin, M., Ehleiter, D.,
Schwartz, J. L., et al. (1994). Basic
fibroblast growth factor protects
endothelial cells against radiation-
induced programmed cell death
in vitro and in vivo. Cancer Res. 54,
2582–2590.
Goldacre, M. J., Wotton, C. J., and
Keenan, T. D. (2012). Risk of selected
eye diseases in people admitted to
hospital for hypertension or diabetes
mellitus: record linkage studies. Br. J.
Ophthalmol. 96, 872–876.
Granoff, D. M., Pandey, J. P., Boies,
E., Squires, J., Munson, R. S., and
Suarez, B. (1984). Response to
immunization with Haemophilus
influenzae type b polysaccharide-
pertussis vaccine and risk of
Haemophilus meningitis in children
with the Km(1) immunoglob-
ulin allotype. J. Clin. Invest. 74,
1708–1714.
Hoogewerf, A. J., Cisar, L. A., Evans,
D. C., and Bensadoun, A. (1991).
Effect of chlorate on the sulfation
of lipoprotein lipase and heparan
sulfate proteoglycans. Sulfation of
heparan sulfate proteoglycans affects
lipoprotein lipase degradation. J.
Biol. Chem. 266, 16564–16571.
Inatani, M., Irie, F., Plump, A. S.,
Tessier-Lavigne, M., and Yamaguchi,
Y. (2003). Mammalian brain mor-
phogenesis and midline axon guid-
ance require heparan sulfate. Science
302, 1044–1046.
Ishizaki, T., Uehata, M., Tamechika, I.,
Keel, J., Nonomura, K., Maekawa,
M., et al. (2000). Pharmacologi-
cal properties of Y-27632, a specific
inhibitor of rho-associated kinases.
Mol. Pharmacol. 57, 976–983.
Kameda, T., Inoue, T., Inatani, M.,
Fujimoto, T., Honjo, M., Kasaoka,
N., et al. (2012). The effect
of Rho-associated protein kinase
inhibitor on monkey Schlemm’s
canal endothelial cells. Invest. Oph-
thalmol. Vis. Sci. 53, 3092–3103.
Kim, H. S., and Park, C. K. (2005). Reti-
nal ganglion cell death is delayed
by activation of retinal intrinsic cell
survival program. Brain Res. 1057,
17–28.
Klein, B. E., Klein, R., and Jensen,
S. C. (1994). Open-angle glaucoma
and older-onset diabetes. The Beaver
Dam Eye Study. Ophthalmology 101,
1173–1177.
Kuehn, M. H., Fingert, J. H., and Kwon,
Y. H. (2005). Retinal ganglion cell
death in glaucoma: mechanisms and
neuroprotective strategies. Ophthal-
mol. Clin. North Am. 18, 383–395.
Kumar, J., and Epstein, D. L. (2011). Rho
GTPase-mediated cytoskeletal orga-
nization in Schlemm’s canal cells
play a critical role in the regulation
of aqueous humor outflow facility. J.
Cell. Biochem. 112, 600–606.
Lee, J. S., von der Hardt, S., Rusch, M.
A., Stringer, S. E., Stickney, H. L.,
Talbot, W. S., et al. (2004). Axon
sorting in the optic tract requires
HSPG synthesis by ext2 (dackel)
and extl3 (boxer). Neuron 44,
947–960.
Leske, M. C., Connell, A. M., Wu, S. Y.,
Hyman, L. G., and Schachat, A. P.
(1994). Risk factors for open-angle
glaucoma. The Barbados Eye Study.
Ophthalmology 101, 1173–1177.
Lucas, A. H., Langley, R. J., Granoff,
D. M., Nahm, M. H., Kitamura, M.
Y., and Scott, M. G. (1991). An
idiotypic marker associated with a
germ-line encoded kappa light chain
variable region that predominates
the vaccine-induced human anti-
body response to the Haemophilus
influenzae b polysaccharide. J. Clin.
Invest. 88, 1811–1818.
Marshall, E. C. (1989). Racial differ-
ences in the presentation of chronic
open-angle glaucoma. J. Am. Optom.
Assoc. 60, 760–767.
Mayer, G., Hamelin, J., Asselin, M.
C., Pasquato, A., Marcinkiewicz, E.,
Tang, M., et al. (2008). The regu-
lated cell surface zymogen activation
of the proprotein convertase PC5A
directs the processing of its secre-
tory substrates. J. Biol. Chem. 283,
2373–2384.
www.frontiersin.org May 2013 | Volume 4 | Article 58 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zimering et al. Autoantibodies in diabetes having glaucoma or dementia
Negishi, M., Lu, D., Zhang, Y. Q.,
Sawada, Y., Sasaki, T., Kayo, T.,
et al. (2001). Upregulatory expres-
sion of furin and transforming
growth factor-beta by fluid shear
stress in vascular endothelial cells.
Arterioscler. Thromb. Vasc. Biol. 21,
785–790.
Ogata-Iwao, M., Inatani, M., Iwao, K.,
Takihara, Y., Nakaishi-Fukuchi, Y.,
Irie, F., et al. (2011). Heparan sulfate
regulates intraretinal axon pathfind-
ing by retinal ganglion cells. Invest.
Ophthalmol. Vis. Sci. 52, 6671–6679.
Properzi, F., Lin, R., Kwok, J., Naidu, M.,
van Kuppevelt, T. H., Ten Dam, G.
B., et al. (2008). Heparan sulphate
proteoglycans in glia and in the nor-
mal and injured CNS: expression
of sulphotransferases and changes
in sulphation. Eur. J. Neurosci. 27,
593–604.
Quigley, H. A. (2011). Glaucoma. Lancet
377, 1367–1377.
Remacle, A. G., Shiryaev, S. A., Oh, E. S.,
Cieplak, P., Srinivasan, A., Wei, G., et
al. (2008). Substrate cleavage analy-
sis of furin and related proprotein
convertases. A comparative study. J.
Biol. Chem. 283, 20897–20906.
Ryu, J. K., and McLarnon, J. G. (2009).
A leaky blood-brain barrier, fibrino-
gen infiltration and microglial reac-
tivity in inflamed Alzheimer’s dis-
ease brain. J. Cell. Mol. Med. 13,
2911–2925.
Scholefield, Z., Yates, E. A., Wayne,
G., Amour, A., McDowell, W., and
Turnbull, J. E. (2003). Heparan
sulfate regulates amyloid precursor
protein processing by BACE1, the
Alzheimer’s beta-secretase. J. Cell
Biol. 163, 97–107.
Shackelford, P. G., Granoff, D. M.,
Nahm, M. H., Scott, M. G., Suarez,
B., Pandey, J. P., et al. (1985). Rela-
tion of age, race, and allotype to
immunoglobulin subclass concen-
trations. Pediatr. Res. 19, 846–849.
Sommer, A. (1996). Glaucoma risk fac-
tors observed in the Baltimore Eye
Survey. Curr. Opin. Ophthalmol. 7,
93–98.
Soto, I., Rosenthal, J. J., Blagburn, J. M.,
and Blanco, R. E. (2006). Fibroblast
growth factor 2 applied to the optic
nerve after axotomy up-regulates
BDNF and TrkB in ganglion cells
by activating the ERK and PKA sig-
naling pathways. J. Neurochem. 96,
82–96.
Stewart, L. L., Field, L. L., Ross, S.,
and McArthur, R. G. (1993). Genetic
risk factors in diabetic retinopathy.
Diabetologia 36, 1293–1298.
Tamura, H., Kawakami, H., Kanamoto,
T., Kato, T., Yokoyama, T., Sasaki,
K., et al. (2006). High frequency
of open-angle glaucoma in Japanese
patients with Alzheimer’s disease. J.
Neurol. Sci. 246, 79–83.
Tezel, G., Edward, D. P., and Wax, M.
B. (1999). Serum autoantibodies to
optic nerve head glycosaminogly-
cans in patients with glaucoma. Arch.
Ophthalmol. 117, 917–924.
Tezel, G., and Wax, M. B. (2004). The
immune system and glaucoma. Curr.
Opin. Ophthalmol. 15, 80–84.
Tura, A., Schuettauf, F., Monnier, P. P.,
Bartz-Schmidt, K. U., and Henke-
Fahle, S. (2009). Efficacy of Rho-
kinase inhibition in promoting cell
survival and reducing reactive gliosis
in the rodent retina. Invest. Ophthal-
mol. Vis. Sci. 50, 452–461.
Uehata, M., Ishizaki, T., Satoh, H., Ono,
T., Kawahara, T., Morishita, T., et
al. (1997). Calcium sensitization of
smooth muscle mediated by a Rho-
associated protein kinase in hyper-
tension. Nature 389, 990–994.
van Paassen, P., Duijvestijn, A.,
Debrus-Palmans, L., Damoiseaux,
J., Vroomen, M., and Tervaert, J. W.
(2007). Induction of endothelial cell
apoptosis by IgG antibodies from
SLE patients with nephropathy: a
potential role for anti-endothelial
cell antibodies. Ann. N. Y. Acad. Sci.
1108, 147–156.
Wax, M. B., Tezel, G., Yang, J., Peng,
G., Patil, R. V., Agarwal, N., et al.
(2008). Induced autoimmunity to
heat shock proteins elicits glaucoma-
tous loss of retinal ganglion cell neu-
rons via activated T-cell-derived fas-
ligand. J. Neurosci. 28, 12085–12096.
Williams, G. C. (1957). Pleiotropy, nat-
ural selection, and the evolution of
senescence. Evolution 11, 398–411.
Wu, T. T., and Kabat, E. A. (1970).
An analysis of the sequences of
the variable regions of Bence Jones
proteins and myeloma light chains
and their implications for antibody
complementarity. J. Exp. Med. 132,
211–250.
Zimering, M. B. (2010). Recurrent mac-
ular edema and stroke syndrome in
type 1 diabetes mellitus with potent
endothelial cell inhibitory autoanti-
bodies. Endocr. Pract. 16, 842–850.
Zimering, M. B., Alder, J., Pan,
Z., and Donnelly, R. J. (2011).
Anti-endothelial and anti-neuronal
effects from auto-antibodies in sub-
sets of adult diabetes having a clus-
ter of microvascular complications.
Diabetes Res. Clin. Pract. 93, 95–105.
Zimering, M. B., Anderson, R. J., Luo,
P., Moritz, T., and VADT Investiga-
tors (2008). Plasma basic fibroblast
growth factor is correlated with plas-
minogen activator inhibitor-1 con-
centration in adults from the Vet-
erans Affairs Diabetes Trial. Metab.
Clin. Exp. 57, 1563–1569.
Zimering, M. B.,Anderson, R. J., Moritz,
T. E., Ge, L., and Investigators for the
VADT. (2009a). Low plasma basic
fibroblast growth factor is associated
with laser photocoagulation treat-
ment in adult type 2 diabetes mel-
litus from the Veterans Affairs Dia-
betes Trial. Metab. Clin. Exp. 58,
393–400.
Zimering, M. B.,Anderson, R. J., Moritz,
T. E., Ge, L., and VADT Inves-
tigators (2009b). Endothelial cell
inhibitory auto-antibodies are asso-
ciated with laser photocoagulation
in adults from the Veterans Affairs
Diabetes Trial. Metab. Clin. Exp. 58,
882–887.
Zimering, M. B., and Pan, Z. (2009).
Autoantibodies in type 2 diabetes
induce stress fiber formation and
apoptosis in endothelial cells. J. Clin.
Endocrinol. Metab. 94, 2171–2177.
Zimering, M. B., and Thakker-Varia, S.
(2002). Increased fibroblast growth
factor-like autoantibodies in serum
from a subset of patients with
cancer-associated hypercalcemia.
Life Sci. 71, 2939–2959.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 25 March 2013; paper pend-
ing published: 18 April 2013; accepted:
01 May 2013; published online: 15 May
2013.
Citation: Zimering MB, Moritz TE and
Donnelly RJ (2013) Anti-neurotrophic
effects from autoantibodies in adult dia-
betes having primary open angle glau-
coma or dementia. Front. Endocrinol.
4:58. doi: 10.3389/fendo.2013.00058
This article was submitted to Frontiers
in Diabetes, a specialty of Frontiers in
Endocrinology.
Copyright © 2013 Zimering , Moritz and
Donnelly. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Endocrinology | Diabetes May 2013 | Volume 4 | Article 58 | 10
